PriceTargets.com logo

PaxMedica - PXMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 333.53%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.69 As of 04/24/2024 01:00 AM ET
▼ -0.02 (-2.81%)

This chart shows the closing price for PXMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PaxMedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PXMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PXMD

Analyst Price Target is $3.00
▲ +333.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for PaxMedica in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 333.53% upside from the last price of $0.69.

This chart shows the closing price for PXMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in PaxMedica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/4/2023HC WainwrightReiterated RatingBuy$3.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 13 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PaxMedica logo
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Read More

Today's Range

Now: $0.69
Low: $0.68
High: $0.72

50 Day Range

MA: $0.61
Low: $0.41
High: $0.84

52 Week Range

Now: $0.69
Low: $0.37
High: $29.75

Volume

255,538 shs

Average Volume

1,948,397 shs

Market Capitalization

$5.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of PaxMedica?

The following Wall Street research analysts have issued stock ratings on PaxMedica in the last twelve months: HC Wainwright.
View the latest analyst ratings for PXMD.

What is the current price target for PaxMedica?

1 Wall Street analysts have set twelve-month price targets for PaxMedica in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 333.5%. HC Wainwright has the highest price target set, predicting PXMD will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for PaxMedica in the next year.
View the latest price targets for PXMD.

What is the current consensus analyst rating for PaxMedica?

PaxMedica currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PXMD will outperform the market and that investors should add to their positions of PaxMedica.
View the latest ratings for PXMD.

What other companies compete with PaxMedica?

Other companies that are similar to PaxMedica include Sonnet BioTherapeutics, Kintara Therapeutics, Alzamend Neuro, Synaptogenix and Bright Minds Biosciences. Learn More about companies similar to PaxMedica.

How do I contact PaxMedica's investor relations team?

The company's listed phone number is 914-987-2876 and its investor relations email address is [email protected]. The official website for PaxMedica is www.paxmedica.com. Learn More about contacing PaxMedica investor relations.